LRG1 Protein Discovery: New Hope for Preventing Diabetic Retinopathy & Vision Loss

A newly identified protein, LRG1, appears to play a critical role in the early stages of diabetic retinopathy, a leading cause of vision loss among working-age adults. This discovery, spearheaded by researchers at the UCL Institute of Ophthalmology, offers a potential new avenue for preventing blindness in people living with diabetes, shifting the focus from managing damage to proactively protecting vision.

Understanding Diabetic Retinopathy and Current Limitations

Diabetic retinopathy develops when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Whereas it affects individuals with both type 1 and type 2 diabetes, current treatments often aren’t effective until significant and irreversible damage has already occurred. Existing therapies primarily target another protein, vascular endothelial growth factor (VEGF), but these only work for roughly half of patients and rarely restore lost vision. Diabetes UK highlights the need for more effective early interventions.

LRG1: A Key Player in Early Retinal Damage

The research, published in Science Translational Medicine, pinpoints LRG1 as a key initiator of retinal damage. Researchers found that this protein causes the cells surrounding the eye’s smallest blood vessels to constrict excessively, effectively ‘squeezing’ them. This constriction reduces oxygen supply to the retina, initiating a cascade of events that can ultimately lead to vision impairment. Importantly, in experiments using mouse models of diabetes, blocking LRG1 activity prevented this early damage and preserved healthy eye function. ScienceDaily reports that the finding could pave the way for treatments that protect vision before symptoms even start.

How the Discovery Was Made

The breakthrough builds on years of research by the UCL Institute of Ophthalmology team, led by Dr. Giulia De Rossi. Professors John Greenwood and Stephen Moss were instrumental in first identifying LRG1’s role in ocular disease. Their work led to the founding of Senya Therapeutics, a UCL spinout company dedicated to developing drugs that target LRG1. This collaborative effort, supported by funding from Diabetes UK, Moorfields Eye Charity and Wellcome, underscores the importance of sustained investment in basic scientific research. UCL’s news release details the funding sources and collaborative nature of the study.

What This Means for People with Diabetes

The identification of LRG1 as an early trigger for diabetic retinopathy is significant as it suggests a window of opportunity for intervention before irreversible damage occurs. Currently, many people are diagnosed with retinopathy only after they experience symptoms like blurred or distorted vision. By the time symptoms appear, substantial damage may already be present. A treatment targeting LRG1 could potentially intervene much earlier, preventing the progression of the disease altogether. Dr. De Rossi explains, “Our discovery shows that diabetic eye disease starts earlier than we thought, and LRG1 is a key culprit in this early damage. Targeting this protein could give us a way to protect vision before serious damage occurs and prevent, rather than treat, blindness in millions of people living with diabetes.”

The Path Forward: From Preclinical Research to Clinical Trials

The UCL research team has already developed a drug designed to target LRG1. This treatment has shown promise in earlier studies and is currently undergoing further preclinical research. Scientists anticipate that it could move into human clinical trials in the near future. The process of bringing a new therapy to market is lengthy and complex, involving multiple phases of clinical trials to assess safety and efficacy.

Understanding Clinical Trial Phases

• Phase 1: Focuses on safety and dosage in a small group of people.
• Phase 2: Evaluates effectiveness and side effects in a larger group.
• Phase 3: Confirms effectiveness, monitors side effects, compares to commonly used treatments, and collects information that will allow the drug or treatment to be used safely.

Even if clinical trials are successful, it will capture time before a LRG1-targeting therapy becomes widely available. However, the discovery represents a significant step forward in the fight against diabetic blindness.

The Broader Context of Diabetic Eye Disease

Nearly a third of adults with diabetes exhibit some signs of retinopathy, making it one of the most feared complications of the condition. Diabetes UK emphasizes the importance of regular eye screening appointments for people with diabetes, as these can detect early signs of damage. However, as current treatments are limited in their ability to address early-stage disease, preventing the onset of damage is a crucial goal. The research on LRG1 offers a promising new strategy for achieving this.

Dr. Ailish Murray, director of grants and research at Moorfields Eye Charity, notes that the early stages of diabetic retinopathy are often difficult to detect, leaving many people with irreversible damage by the time symptoms appear. This research offers a vital step in preventing this disease and potentially saving the sight of millions.

What to expect moving forward: Researchers will continue to refine the LRG1-targeting therapy and prepare for clinical trials. Ongoing research will likewise focus on identifying individuals who are most likely to benefit from this treatment. Public health organizations will continue to emphasize the importance of diabetes management and regular eye screenings.